;
Skip to main content
Home > The Daily Extra > Financial News

Chronological Index of : Financial News

 Current Issue
  • FINANCIAL NEWS: Blueprint raises $50 million in series C

    Blueprint Medicines (Cambridge, Mass.) raised $50 million in an untranched series C round led by new investor Partner Fund Management. Other new investors included Wellington Management; RA Capital; Tavistock Life …

    Published on 11/12/2014
  • FINANCIAL NEWS: Isis raises $425M in note deal

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS) raised $425 million through the sale of senior unsecured convertible notes. The notes bear 1% interest, mature in 2021 and initially convert at $66.81.The company will use a …

    Published on 11/12/2014
  • FINANCIAL NEWS: Isis planning $425M note deal

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS) proposed to raise $425 million in a private placement of senior unsecured convertible notes due 2021. The company intends to use a portion of the capital to repurchase $140 …

    Published on 11/11/2014
  • FINANCIAL NEWS: Neothetics sets IPO terms

    Neothetics Inc. (San Diego, Calif.) set terms for its IPO on NASDAQ and plans to sell 4.3 million shares at $13-$15. At $14, Neothetics would raise $60.2 million and be valued at $185.7 million. Piper Jaffray; …

    Published on 11/10/2014
  • FINANCIAL NEWS: Ziarco raises $33.1M series B

    Ziarco Pharma Ltd. (Canterbury, U.K.) raised $33.1 million in a series B round led by New Enterprise Associates and Lundbeckfond Ventures. New investor Amgen Ventures and existing investors BVF Partners and Pfizer …

    Published on 11/10/2014
  • FINANCIAL NEWS: Coherus raises $85M in IPO

    Coherus BioSciences Inc. (NASDAQ:CHRS) fell $0.89 to $12.61 in its first day of trading Thursday after raising $85 million in an IPO on NASDAQ through the sale of 6.3 million shares at $13.50. The IPO price valued …

    Published on 11/6/2014
  • FINANCIAL NEWS: Sanderling backs IRCM spinout Liphorus

    Liphorus Pharmaceuticals Inc. (Montreal, Quebec) raised $6.4 million in a series A round from Sanderling Ventures. The startup plans to develop small molecules targeting proprotein convertase subtilisin/kexin type 9 (…

    Published on 11/6/2014
  • FINANCIAL NEWS: CP Group planning investments in Karolinska

    Karolinska Development AB (SSE:KDEV) jumped SEK2.50 (18%) to SEK16.10 on Wednesday after it said Charoen Pokphand Group (Bangkok, Thailand) and its affiliates would invest in the company.First, Karolinska said it plans …

    Published on 11/5/2014
  • FINANCIAL NEWS: IPO roundup: Xenon, Molecular Partners price; Inotek files

    Xenon Pharmaceuticals Inc. (NASDAQ:XENE) and Molecular Partners AG (SIX:MOLN) each priced IPOs and began trading, while Inotek Pharmaceuticals Corp. (Lexington, Mass.) filed for a new listing.Xenon gained $1.50 (17%) to…

    Published on 11/5/2014
  • FINANCIAL NEWS: Achillion loses a lot after saying little

    Shares of HCV play Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) dropped $1.89 (16%) to $10.23 after the company released 3Q14 earnings with no updates for two highly anticipated clinical studies of its HCV compounds ACH…

    Published on 11/4/2014
  • FINANCIAL NEWS: Merieux closes EUR150M healthcare fund

    Merieux Developpement, the private equity arm of Institut Merieux, has launched its second evergreen healthcare fund with EUR150 million ($187.4 million). The fund includes a EUR75 million contribution from Sienna …

    Published on 11/4/2014
  • FINANCIAL NEWS: Molecular Partners, Neuroderm set IPO terms

    Molecular Partners AG (Schlieren, Switzerland) re-entered the IPO queue with a downsized offering on the SIX Swiss Exchange less than two weeks after postponing the listing due to market conditions, while NeuroDerm Ltd.…

    Published on 11/3/2014
  • FINANCIAL NEWS: Chimerix rises with its bank account

    Chimerix Inc. (NASDAQ:CMRX) gained $1.15 to $31.04 after completing its second big follow-on in 2014. The infectious disease company raised $105.9 million through the sale of 3.65 million shares at $29 in a deal …

    Published on 10/31/2014
  • FINANCIAL NEWS: Imago raises $26.5M series A

    Myeloid malignancy company Imago BioSciences Inc. (San Francisco, Calif.) raised $26.5 million in a series A round led by Clarus Ventures. Frazier Healthcare; Amgen Ventures; and Merck Research Labs Venture Fund also …

    Published on 10/31/2014
  • FINANCIAL NEWS: PolyPid sets IPO terms

    PolyPid Ltd. (Petach Tikva, Israel) amended its proposed IPO on NASDAQ and now plans to sell 1.8 million shares at $10-$12. At $11, PolyPid would raise $20 million and be valued at $103 million. Aegis Capital; MLV; and …

    Published on 10/31/2014
  • FINANCIAL NEWS: Venture tracks

    Clarus Ventures named Barry Gertz a venture partner. He also will become chief medical advisor for Clarus portfolio company Relay Pharmaceuticals Inc., which finances late-stage clinical studies of pharma assets. Gertz …

    Published on 10/31/2014
  • FINANCIAL NEWS: Virobay pulls IPO

    Virobay Inc. (Menlo Park, Calif.) withdrew its proposed IPO on NASDAQ, citing market conditions. Earlier this month, the company amended its offering to sell 3.8 million shares at $12-$14. At $13, it would have raised $…

    Published on 10/31/2014
  • FINANCIAL NEWS: Cortendo pulls Oslo IPO to mull U.S. listing, raises $11.3M

    Cortendo AB (Gothenburg, Sweden) said it will raise SEK 81.5 million ($11.3 million) in a private placement. The company will also drop plans to list on the Oslo Axess exchange and consider a U.S. listing instead.The …

    Published on 10/30/2014
  • FINANCIAL NEWS: FibroGen targeting near-billion dollar valuation

    FibroGen Inc. (San Francisco, Calif.) set terms for its IPO on NASDAQ and plans to sell 7.1 million shares at $16-$19. At $17.50, the company would raise $124.3 million and be valued at $974.3 million. Goldman Sachs; …

    Published on 10/30/2014
  • FINANCIAL NEWS: Incyte jumps on Jakafi trajectory

    Incyte Corp. (NASDAQ:INCY) jumped $6.31 (11%) to $64.18 on Thursday after its 3Q14 earnings beat Street expectations, including a 63% increase in Jakafi ruxolitinib sales compared to 3Q13.Jakafi, sold outside the U.S. …

    Published on 10/30/2014
  • FINANCIAL NEWS: Pacira dinged on Exparel "disruptions"

    Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) fell $14.70 (14%) to $91.11 on Thursday as investors digested comments on the company's earnings call related to a previously announced September warning letter from FDA about …

    Published on 10/30/2014
  • FINANCIAL NEWS: Rhythm withdraws IPO after Actavis deal

    Rhythm Pharmaceuticals Inc. (Boston, Mass.) withdrew its proposed IPO on NASDAQ. Last week, the company received $40 million up front in a deal giving Actavis plc (NYSE:ACT) an option to acquire a Rhythm subsidiary that…

    Published on 10/30/2014
  • FINANCIAL NEWS: Chimerix planning $105M follow-on

    Chimerix Inc. (NASDAQ:CMRX) said it plans to raise about $105 million in a follow-on underwritten by Morgan Stanley; JP Morgan; Cowen; Piper Jaffray; and Stifel, Nicolaus.Chimerix's brincidofovir is in Phase III trials …

    Published on 10/29/2014
  • FINANCIAL NEWS: Regulus raises $75M in follow-on

    Regulus Therapeutics Inc. (NASDAQ:RGLS) wasted little time cashing in on a recent stock surge, as the microRNA company raised $75 million through the sale of 4.4 million shares at $17 in a follow-on underwritten by …

    Published on 10/29/2014
  • FINANCIAL NEWS: Synergy raises $175M in note deal

    Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) raised $175 million through the sale of senior unsecured convertible notes. The notes bear 7.5% interest, mature in 2019 and initially convert at $3.11. Synergy's lead compound…

    Published on 10/29/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993